{
    "id": 17856,
    "fullName": "MSLN positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MSLN positive indicates the presence of the MSLN gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 10232,
        "geneSymbol": "MSLN",
        "terms": [
            "MSLN",
            "MPF",
            "SMRP"
        ]
    },
    "variant": "positive",
    "createDate": "02/11/2016",
    "updateDate": "01/08/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4461,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, 58% (19/33) of evaluable mesothelioma, ovarian cancer or pancreatic cancer MSLN positive patients had stable disease after SS1P treatment (PMID: 17785569).",
            "molecularProfile": {
                "id": 18164,
                "profileName": "MSLN positive"
            },
            "therapy": {
                "id": 3520,
                "therapyName": "SS1P",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4561,
                    "pubMedId": 17785569,
                    "title": "Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17785569"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16222,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, 8% (2/26) of patients with pancreatic cancer, potentially positive for Msln, demonstrated a partial response, lasting 1.4 months and 12.1 months, when treated with DMOT4039A, while nine patients experienced stable disease as best response (PMID: 26823490; NCT01469793).",
            "molecularProfile": {
                "id": 18164,
                "profileName": "MSLN positive"
            },
            "therapy": {
                "id": 7944,
                "therapyName": "DMOT4039A",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14346,
                    "pubMedId": 26823490,
                    "title": "Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26823490"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16223,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, 30% (3/10) of patients with ovarian cancer, potentially positive for Msln, demonstrated a confirmed partial response of 2.7 mo, 3.6 mo, and 4.1 mo, with concurrent CA125 responses while 8% (1/12) demonstrated a RECIST response that lasted 5.7 mo when treated with DMOT4039A (PMID: 26823490; NCT01469793).",
            "molecularProfile": {
                "id": 18164,
                "profileName": "MSLN positive"
            },
            "therapy": {
                "id": 7944,
                "therapyName": "DMOT4039A",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14346,
                    "pubMedId": 26823490,
                    "title": "Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26823490"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18164,
            "profileName": "MSLN positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}